肝组织来源细胞外囊泡促进颌骨缺损愈合的研究
该研究探讨肝组织来源细胞外囊泡(LT-EV)促进间充质干细胞成骨分化及颌骨缺损愈合的生物学过程。通过小鼠颌骨缺损模型和人颌骨间充质干细胞实验,发现LT-EV可到达缺损区域并促进骨再生,骨体积分数显著提高,且具有良好的生物安全性,有望成为颅颌面骨缺损再生的无细胞治疗新策略。
要点
- LT-EV产量高、易获取,可到达颌骨缺损区域并促进骨再生。
- LT-EV组骨体积分数显著高于对照组,具有良好的生物安全性。
- LT-EV在体外可增强人颌骨间充质干细胞的成骨分化能力。
核心结论
- LT-EV产量大、易获取、生物安全性高并具备优良的促成骨作用,有望成为颅颌面骨骼缺损再生的无细胞疗法新策略。
研究设计与样本
- 使用酶解法和差速离心法提取小鼠LT-EV,并通过扫描电镜、蛋白质印迹法和纳米粒子跟踪分析仪进行鉴定和表征。
- 通过简单随机抽样法将6只C57BL/6小鼠分为对照组和LT-EV组(每组3只),所有小鼠行颌骨缺损手术,每7天尾静脉注射,术后28天评估愈合。
- 采用LT-EV处理成骨分化诱导的人颌骨间充质干细胞(hJBMSC),比较成骨分化能力差异。
主要发现
- LT-EV产量较高,蛋白质组学和京都基因和基因组数据库通路分析显示其含有调节细胞生物功能的系列蛋白质。
- 尾静脉注射的LT-EV可到达小鼠颌骨缺损区域,并促进颌骨缺损的再生修复,LT-EV组和对照组骨体积分数分别为(36.06±4.20)%和(18.58±5.61)%(t=4.32,P=0.013)。
- LT-EV具有良好的生物安全性。
- LT-EV在体外可促进hJBMSC成骨分化,相比对照组,ALP染色和成骨基因表达水平均显著增强(P<0.05)。
临床怎么用
- LT-EV有望作为无细胞疗法新策略用于颅颌面骨骼缺损再生的临床治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the biological process of liver tissue-derived extracellular vesicle (LT-EV) in promoting osteogenic differentiation of mesenchymal stem cells and healing of jaw defects to provide a feasible treatment method for the clinical treatment of jaw bone defects. Methods: Enzymatic hydrolysis and differential centrifugation were used to extract LT-EV, scanning electron microscopy, Western blotting, and nanoparticle tracking analyzers were used to identify and characterize LT-EV, and further to explore the biological functions of LT-EV through proteomics and Kyoto Encyclopedia of Genes and Genomes. Flow cytometry was used to detect LT-EV plasma concentration and to calculate the plasma half-life of LT-EV. Small animal in vivo imaging system was used to detect the biological distribution of LT-EV 24 hours after injection. Six C57BL/6 mice were divided into control group and LT-EV group (3 mice in each group) by simple random sampling method. All mice underwent jaw bone defect surgery and tail vein injection every 7 days (the control group was injected with phosphoric buffer saline, LT-EV group was injected with LT-EV), micro-CT was used to evaluate the degree of mouse jaw bone healing 28 days after surgery, HE staining was used to analyze the multi-organ biosafety of LT-EV, and immunofluorescence staining was used to detect the jaw bone expression of osteogenic marker proteins in the defect area. Human jaw bone mesenchymal stem cells (hJBMSC) induced by osteogenic differentiation were treated with LT-EV (obtained from orthognathic surgery patients provided by the Department of Traumatology and Orthognathic Surgery of School of Stomatology of The Fourth Military Medical University resected normal jaw bone fragments), and the difference in osteogenic differentiation ability between the hJBMSC group and the control group (phosphate buffer saline treatment) was compared, and the in vitro bone differentiation promoting effect of LT-EV was verified through alkaline phosphatase (ALP) staining and real-time fluorescence quantitative PCR. Results: The yield of LT-EV was high, and proteomics and Kyoto Encyclopedia of Genes and Genomes showed that LT-EV contained a series of proteins that regulated cell biological functions. LT-EV injected into the tail vein could reach the mouse jaw bone defect area and promote the regeneration and repair of the jaw bone defect [the bone volume fractions of the LT-EV group and the control group were (36.06±4.20)% and (18.58±5.61)%, respectively; t=4.32, P=0.013], and had good biosafety. LT-EV could promote osteogenic differentiation of hJBMSC in vitro. Compared to the control group, ALP staining and osteogenic gene expression levels were significantly enhanced after osteogenic differentiation of hJBMSC (P<0.05). Conclusions: LT-EV exhibits a high yield, ease of acquisition, high biological safety, and excellent bone-promoting effects. It holds promise as a novel cell-free therapy strategy for regenerating craniofacial bone defects. 目的: 探讨肝组织细胞外囊泡(LT-EV)促进间充质干细胞成骨分化并治疗小鼠颌骨缺损的生物学过程,以期为临床颌骨缺损治疗提供一种可行的治疗方式。 方法: 使用酶解法和差速离心法提取小鼠LT-EV,使用扫描电镜、蛋白质印迹法和纳米粒子跟踪分析仪鉴定和表征LT-EV,并通过蛋白质组学、京都基因和基因组数据库通路分析进一步探索LT-EV的生物学功能。使用流式细胞术检测LT-EV血浆浓度,计算LT-EV的血浆半衰期。使用小动物活体成像系统检测小鼠注射LT-EV 24 h后的生物学分布。通过简单随机抽样法将6只C57BL/6小鼠分为对照组和LT-EV组(每组3只),所有小鼠行颌骨缺损手术,每7天行尾静脉注射(对照组注射磷酸盐缓冲液,LT-EV组注射LT-EV),术后28 d使用显微CT检测小鼠颌骨愈合程度,通过HE染色分析LT-EV的多器官生物安全性,使用免疫荧光染色检测颌骨缺损区域成骨标志蛋白表达量。采用LT-EV处理成骨分化诱导的人颌骨间充质干细胞(hJBMSC)(取自第四军医大学口腔医院创伤与正颌外科提供的正颌手术患者手术切除的正常颌骨骨片),并比较hJBMSC组与对照组(磷酸盐缓冲液处理)细胞成骨分化能力差异,通过碱性磷酸酶(ALP)染色和实时荧光定量PCR验证LT-EV的体外促成骨分化作用。 结果: LT-EV产量较高,蛋白组学与京都基因和基因组数据库通路分析显示,LT-EV含有调节细胞生物功能的系列蛋白质。尾静脉注射的LT-EV可到达小鼠颌骨缺损区域,并促进颌骨缺损的再生修复[LT-EV组和对照组骨体积分数分别为(36.06±4.20)%和(18.58±5.61)%;t=4.32,P=0.013],且具有良好的生物安全性。LT-EV在体外可以促进hJBMSC成骨分化,相比对照组,hJBMSC组成骨分化后ALP染色和成骨基因表达水平均显著增强(P<0.05)。 结论: LT-EV产量大、易获取、生物安全性高并具备优良的促成骨作用,有望成为颅颌面骨骼缺损再生的无细胞疗法新策略。.
引用
- Li CH, Lei X, Zheng CX, et al. [Study on liver tissue derived-extracellular vesicles regulating the osteogenic differentiation ability of mesenchymal stem cells and promoting the healing of jaw bone defects]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2024. PMID: 38636997. doi:10.3760/cma.j.cn112144-20240224-00087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。